Seven decades of data on the same families, watching how brains age.
For more than seven decades, the families of Framingham, Massachusetts have offered science something rare: a living record of how human bodies and minds age across generations. Now, a $26.56 million NIH grant will deepen that record, directing Boston University researchers to trace the vascular, genetic, and inflammatory roots of Alzheimer's disease with tools and precision unavailable to those who began this work in 1976. The investment reflects a broader reckoning in medicine — that understanding why some minds endure while others decline may require not years of study, but lifetimes.
- Alzheimer's disease remains without a cure or reliable means of prevention, and the urgency to understand its origins has never been greater.
- The NIH's five-year, $26.56 million grant signals a major institutional commitment to unlocking multi-generational biological data that no other study in the world can replicate.
- Three interlocking research projects will probe how chronic inflammation, immune gene variation, and vascular damage conspire — or fail to conspire — to produce cognitive decline.
- A revitalized brain donation program will allow direct neuropathological examination of tissue, bridging the gap between clinical observation and the physical reality of disease.
- An open data-sharing platform is being built to draw in early-career scientists and cross-disciplinary researchers, multiplying the questions the Framingham dataset can answer.
- The program is moving the field's focus from identifying who gets sick toward understanding what keeps some brains resilient — and how to replicate that resilience.
For nearly fifty years, researchers at Boston University have followed the same families through time — tracking hearts, minds, blood pressure, and cholesterol across parents, children, and grandchildren. The Framingham Heart Study began its dementia work in 1976, making it the longest-running multi-generational epidemiological study of its kind. A new five-year, $26.56 million NIH grant will now expand that work into a dedicated Framingham Heart Study Brain Aging Program.
Leading the effort is Lindsay Farrer, chief of biomedical genetics at Boston University School of Medicine, whose career spans more than 450 publications on genetic risk in neurodegenerative disease. His team will pursue three research projects centered on the vascular and inflammatory pathways that contribute to Alzheimer's — examining which factors protect against cognitive decline, how genetic vulnerabilities interact with chronic inflammation, and how immune-function gene variants affect brain health over time.
The program will also reinvigorate the study's brain donation initiative, enabling neuropathological examination of donated tissue alongside decades of clinical and genetic data — a combination capable of surfacing risk factors and biomarkers that would otherwise go undetected.
Rhoda Au, a professor with deep roots in the Framingham cognitive research program since 1990, will lead participant engagement. She pioneered more sensitive neuropsychological testing methods within epidemiological research and has since introduced digital tools capable of detecting cognitive shifts far earlier than traditional assessments allow.
Beyond Boston University, the grant will establish an open data-sharing platform designed to bring new researchers — including those outside the Alzheimer's field — into contact with the Framingham dataset and specimens. The Framingham study has already redrawn public health understanding of heart disease and stroke. This new chapter aims to do the same for dementia: not merely cataloguing who declines, but illuminating why some minds age well — and how that balance might be shifted in more people's favor.
For nearly half a century, researchers at Boston University have been watching the same families age. They've tracked their hearts, their minds, their blood pressure, their cholesterol—generation after generation, from parents to children to grandchildren. The Framingham Heart Study began its work on dementia in 1976, making it the longest-running multi-generational epidemiological study in the world. Now, with a five-year grant of $26.56 million from the National Institutes of Health, that work is about to expand dramatically.
The new initiative, called the Framingham Heart Study Brain Aging Program, will deepen what researchers can learn from this extraordinary dataset. For decades, the study has helped distinguish between the normal cognitive changes that come with age and the pathological alterations that signal disease. By including not just the original participants but also their children and grandchildren, the researchers have built something rare: a window into how genetics, lifestyle, and biology interact across a human lifespan, and how those factors shape the risk of Alzheimer's disease and vascular dementia.
Lindsay Farrer, chief of biomedical genetics at Boston University School of Medicine, will lead the research. His career has already produced more than 450 publications on genetic risk factors in neurodegenerative disease. Under this new program, his team will pursue three interconnected research projects, all focused on understanding the vascular and inflammatory pathways that contribute to Alzheimer's. One project will use seven decades of accumulated data to identify which factors protect people from cognitive decline and which increase their risk. Another will examine how genetic vulnerabilities to Alzheimer's interact with chronic inflammation in the body. A third will investigate how variations in genes that control immune function affect brain changes and cognitive performance.
The program will also revitalize the brain donation initiative that has been central to the study's work. Participants who donate their brains after death allow researchers to conduct neuropathological examinations—direct inspection of brain tissue to identify the physical hallmarks of disease. This kind of work, combined with the clinical and genetic information already collected, creates opportunities to discover new risk factors and biomarkers that might otherwise remain hidden.
Rhoda Au, a professor of anatomy, neurobiology, neurology, and epidemiology at Boston University, will coordinate participant engagement. She has been involved in the Framingham study's cognitive research since 1990 and pioneered the use of the Boston Process Approach—a more sensitive neuropsychological testing method—within epidemiological research. More recently, she has introduced digital technologies to detect cognitive changes far more precisely than traditional paper-and-pencil tests ever could. Her work reflects a broader shift in how researchers think about brain health: not just identifying disease, but understanding the conditions under which cognition and memory can be preserved.
One of the program's explicit goals is to accelerate research beyond the Boston University team itself. The grant will establish a platform for data sharing, designed to bring in early-career researchers and scientists who have not traditionally worked in the Alzheimer's field. By opening access to the Framingham data and specimens, the program aims to multiply the number of research questions that can be asked and answered.
The Framingham Heart Study has already reshaped public health understanding multiple times over. It established the links between cholesterol and heart disease, between blood pressure and stroke. It identified precursors to diseases of aging that clinicians now take for granted. With this new investment, the study is positioned to do something similar for dementia—to move beyond identifying who gets sick and toward understanding why some people's brains age well and others do not, and what interventions might tip the balance.
Notable Quotes
The primary goal is to continue dementia surveillance, bring added resources to the brain donation program, and identify new and expand on known Alzheimer's-related genetic and other risk factors and biomarkers.— Lindsay Farrer, chief of biomedical genetics at Boston University School of Medicine
Investigators will apply inter-disciplinary approaches to develop strategies that preserve cognition and memory and identify novel therapeutic targets.— Rhoda Au, professor of anatomy and neurobiology at Boston University
The Hearth Conversation Another angle on the story
Why does it matter that this study has been running for so long? Couldn't you just start fresh with new participants?
You could, but you'd lose something irreplaceable. These researchers have been watching the same people for decades—tracking their cholesterol in 1976, their brain scans in 2020. You can't recreate that arc. You can see how a person's life actually unfolds, not just guess based on a snapshot.
So the three-generation piece—that's about genetics?
Partly. But it's also about seeing patterns repeat. If a parent had cognitive decline at 75, does the child show early signs at 65? What's inherited, what's environmental, what's just chance? You need families to untangle that.
The brain bank—that sounds clinical. What's actually happening there?
When someone dies, their family can donate their brain. Researchers slice it, examine it under a microscope, look for the physical tangles and plaques that define Alzheimer's. Then they match that pathology against everything else they know about that person—their genes, their lifestyle, their test scores from decades earlier. That's where real insight lives.
Why focus on inflammation and vascular disease specifically?
Because Alzheimer's isn't just one thing. Some people have the classic plaques and tangles but never developed symptoms. Others had vascular damage—tiny strokes, blood vessel problems—that seemed to tip them into cognitive decline. The field is moving away from a single-cause theory toward understanding how multiple systems interact.
And the data sharing—that's about democratizing the research?
Exactly. Right now, if you're a young researcher with a novel idea about immune function and dementia, you might not have access to the data you need to test it. This program says: here's 70 years of information on thousands of people. What questions can you answer?
What would success look like five years from now?
New genetic risk factors identified. Better biomarkers that predict who will decline. Maybe a therapeutic target that didn't exist before. But also: a generation of researchers trained on this data, asking questions we haven't thought to ask yet.